Ask AI
Public Law117th CongressHealth
H.R. 1193Became Law

Cardiovascular Advances in Research and Opportunities Legacy Act

This bill became law

Filed
Comm.
Floor
Both
Law

What it doesSummary public law (Dec 20, 2022)

Cardiovascular Advances in Research and Opportunities Legacy Act

This act addresses research, education, and awareness concerning valvular heart disease and its treatment. This disease is caused by damage to or disease affecting any valve that controls blood flow in the heart.

The National Institutes of Health may conduct or support research on the disease in consultation with the National Heart, Lung, and Blood Institute (NHLBI). The NHLBI must also conduct a workshop on mitral valve prolapse, which occurs when the valve between the chambers of the left side of the heart seals improperly.

The Department of Health and Human Services (HHS) must develop best practices to treat valvular heart disease. HHS may also carry out other projects to increase education and awareness of the disease.

What just happenedDec 20, 2022

Became Public Law No: 117-244.

Who’s behind it

Rep. Barr, Andy [R-KY-6](R-KY)Sponsor
183 cosponsors70 D113 R
Read on Congress.gov
183cosponsors2committees40actions1amendments1related bills11subjects
  1. Dec 20, 2022President

    Became Public Law No: 117-244.

  2. Dec 20, 2022BecameLaw36000

    Became Public Law No: 117-244.

  3. Dec 20, 2022President

    Signed by President.

  4. Dec 20, 2022BecameLaw36000

    Signed by President.

  5. Dec 16, 2022Floor

    Presented to President.

  6. Dec 16, 2022President28000

    Presented to President.

  7. Dec 5, 2022ResolvingDifferencesH41931

    Motion to reconsider laid on the table Agreed to without objection.

  8. Dec 5, 2022ResolvingDifferencesH41610

    On motion that the House suspend the rules and agree to the Senate amendment Agreed to by voice vote. (text: CR H8755)

  9. Dec 5, 2022NotUsed19500

    Resolving differences -- House actions: On motion that the House suspend the rules and agree to the Senate amendment Agreed to by voice vote.

  10. Dec 5, 2022FloorH8D000

    DEBATE - The House proceeded with forty minutes of debate on the Senate amendment to H.R. 1193.

  11. Dec 5, 2022ResolvingDifferencesH40140

    Mr. Pallone moved that the House suspend the rules and agree to the Senate amendment. (consideration: CR H8755-8756)

  12. Dec 5, 2022Floor

    Message on Senate action sent to the House.

  13. Dec 1, 2022Floor

    Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S6947)

  14. Dec 1, 2022Floor17000

    Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.(text of amendment in the nature of a substitute: CR S6947)

  15. Dec 1, 2022Floor

    The committee substitute withdrawn by Unanimous Consent.

  16. Dec 1, 2022Floor

    Measure laid before Senate by unanimous consent. (consideration: CR S6946-6947)

  17. Jul 12, 2022Calendars

    Placed on Senate Legislative Calendar under General Orders. Calendar No. 443.

  18. Jul 12, 2022Committee

    Committee on Health, Education, Labor, and Pensions. Reported by Senator Murray with an amendment in the nature of a substitute. Without written report.

    Health, Education, Labor, and Pensions Committee
  19. Jul 12, 2022Committee14000

    Committee on Health, Education, Labor, and Pensions. Reported by Senator Murray with an amendment in the nature of a substitute. Without written report.

    Health, Education, Labor, and Pensions Committee
  20. Jun 14, 2022Committee

    Committee on Health, Education, Labor, and Pensions. Ordered to be reported without amendment favorably.

    Health, Education, Labor, and Pensions Committee
  21. May 25, 2022IntroReferral

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Health, Education, Labor, and Pensions Committee
  22. Dec 9, 2021IntroReferral

    Received in the Senate.

  23. Dec 8, 2021FloorH38800

    The title of the measure was amended. Agreed to without objection.

  24. Dec 8, 2021FloorH38310

    Motion to reconsider laid on the table Agreed to without objection.

  25. Dec 8, 2021FloorH37300

    On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7518)

  26. Dec 8, 2021Floor8000

    Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H7518)

  27. Dec 8, 2021FloorH8D000

    DEBATE - The House proceeded with forty minutes of debate on H.R. 1193.

  28. Dec 8, 2021FloorH30000

    Considered under suspension of the rules. (consideration: CR H7518-7522)

  29. Dec 8, 2021FloorH30300

    Mr. Pallone moved to suspend the rules and pass the bill, as amended.

  30. Dec 8, 2021CalendarsH12410

    Placed on the Union Calendar, Calendar No. 153.

  31. Dec 8, 2021CommitteeH12200

    Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 117-212.

    Energy and Commerce Committee
  32. Dec 8, 2021Committee5000

    Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 117-212.

    Energy and Commerce Committee
  33. Nov 17, 2021Committee

    Ordered to be Reported (Amended) by Voice Vote.

    Energy and Commerce Committee
  34. Nov 17, 2021Committee

    Committee Consideration and Mark-up Session Held.

    Energy and Commerce Committee
  35. Nov 4, 2021Committee

    Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .

    Health Subcommittee
  36. Nov 4, 2021Committee

    Subcommittee Consideration and Mark-up Session Held.

    Health Subcommittee
  37. Feb 23, 2021Committee

    Referred to the Subcommittee on Health.

    Health Subcommittee
  38. Feb 22, 2021IntroReferralH11100

    Referred to the House Committee on Energy and Commerce.

    Energy and Commerce Committee
  39. Feb 22, 2021IntroReferralIntro-H

    Introduced in House

  40. Feb 22, 2021IntroReferral1000

    Introduced in House

Public LawDec 20, 202249

Cardiovascular Advances in Research and Opportunities Legacy Act

This act addresses research, education, and awareness concerning valvular heart disease and its treatment. This disease is caused by damage to or disease affecting any valve that controls blood flow in the heart.

The National Institutes of Health may conduct or support research on the disease in consultation with the National Heart, Lung, and Blood Institute (NHLBI). The NHLBI must also conduct a workshop on mitral valve prolapse, which occurs when the valve between the chambers of the left side of the heart seals improperly.

The Department of Health and Human Services (HHS) must develop best practices to treat valvular heart disease. HHS may also carry out other projects to increase education and awareness of the disease.

House agreed to Senate amendmentDec 5, 202259

Cardiovascular Advances in Research and Opportunities Legacy Act

This bill addresses research, education, and awareness concerning valvular heart disease and its treatment. This disease is caused by damage to or disease affecting any valve that controls blood flow in the heart.

The National Institutes of Health may conduct or support research on the disease in consultation with the National Heart, Lung, and Blood Institute (NHLBI). The NHLBI must also conduct a workshop on mitral valve prolapse, which occurs when the valve between the chambers of the left side of the heart seals improperly.

The Department of Health and Human Services (HHS) must develop best practices to treat valvular heart disease. HHS may also carry out other projects to increase education and awareness of the disease.

Passed SenateDec 1, 202255

Cardiovascular Advances in Research and Opportunities Legacy Act

This bill addresses research, education, and awareness concerning valvular heart disease and its treatment. This disease is caused by damage to or disease affecting any valve that controls blood flow in the heart.

The National Institutes of Health may conduct or support research on the disease in consultation with the National Heart, Lung, and Blood Institute (NHLBI). The NHLBI must also conduct a workshop on mitral valve prolapse, which occurs when the valve between the chambers of the left side of the heart seals improperly.

The Department of Health and Human Services (HHS) must develop best practices to treat valvular heart disease. HHS may also carry out other projects to increase education and awareness of the disease.

Reported to SenateJul 12, 202225

Cardiovascular Advances in Research and Opportunities Legacy Act

This bill addresses research, education, and awareness concerning valvular heart disease and its treatment. This disease is caused by damage to or disease affecting any valve that controls blood flow in the heart.

The National Institutes of Health may conduct or support research on the disease in consultation with the National Heart, Lung, and Blood Institute (NHLBI). The NHLBI must also conduct a workshop on mitral valve prolapse, which occurs when the valve between the chambers of the left side of the heart seals improperly.

The Department of Health and Human Services (HHS) must develop best practices to treat valvular heart disease. HHS may also carry out other projects to increase education and awareness of the disease.

Passed HouseDec 8, 202153

Cardiovascular Advances in Research and Opportunities Legacy Act

This bill expands research on valvular heart disease and its treatment. This disease is caused by damage to or disease affecting any valve that controls blood flow in the heart.

The National Institutes of Health must consult with the National Heart, Lung, and Blood Institute to conduct or support research on the disease, including on mitral valve prolapse. This occurs when the valve between the chambers of the left side of the heart seals improperly.

The Centers for Disease Control and Prevention (CDC) must develop best practices to treat valvular heart disease. The CDC may also carry out other projects to increase awareness of and reduce deaths from the disease.

Introduced in HouseFeb 22, 2021

Cardiovascular Advances in Research and Opportunities Legacy Act

This bill expands research on valvular heart disease and its treatment. This disease is caused by damage to or disease affecting any valve that controls blood flow in the heart.

The National Institutes of Health must consult with the National Heart, Lung, and Blood Institute to conduct or support research on the disease, including on mitral valve prolapse. This occurs when the valve between the chambers of the left side of the heart seals improperly.

The Centers for Disease Control and Prevention (CDC) must develop best practices to treat valvular heart disease. The CDC may also carry out other projects to increase awareness of and reduce deaths from the disease.

Cardiovascular Advances in Research and Opportunities Legacy Act — Informed